Top 50 Life Science Startup Investors in Israel (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Israel Innovation Authority
VC Fund
|
6 | Israel, United States, Mali | Grant, Seed, Pre-Seed | Health Care, Artificial Intelligence, Biotechnology | $100k–$6M |
|
Sapir Venture Partners
VC Fund
|
5 | Israel, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Biotechnology, Analytics | $305k–$40M |
|
aMoon Fund
VC Fund
|
4 | United States, Israel, France | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5.7M–$93M |
|
Integra Holdings
VC Fund
|
4 | Israel | Seed, Series B, Series F | Biotechnology, Pharmaceutical, Life Science | |
|
OrbiMed
VC Fund
|
4 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $9.8M–$160M |
|
FutuRx
VC Fund
|
4 | Israel | Seed, Venture - Series Unknown | Biotechnology, Biopharma, Therapeutics | |
|
Neo Ventures
VC Fund
|
3 | United States, United Kingdom, Israel | Seed, Series A | Software, Artificial Intelligence, SaaS | $500k–$24M |
|
RMGP Biopharma Investment Fund
VC Fund
|
3 | Israel | Seed, Series B, Venture - Series Unknown | Biotechnology, Biopharma, Therapeutics | |
|
Pitango VC
VC Fund
|
3 | Israel, United States, United Kingdom | Series B, Series A, Series C | Software, Health Care, Information Technology | $4M–$100M |
|
Grove Ventures
VC Fund
|
3 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $3.5M–$74M |
|
fresh.fund
VC Fund
|
2 | Israel, United States, Norway | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $300k–$21M |
|
First Star Ventures
VC Fund
|
2 | United States, Canada, Israel | Seed, Pre-Seed, Series A | Software, Biotechnology, Artificial Intelligence | $575k–$15M |
|
Arba Finance Ltd.
VC Fund
|
2 | Israel | Seed, Series A | AgTech, Medical, Cannabis | |
|
Jerusalem Venture Partners (JVP)
VC Fund
|
2 | United States, Israel, United Kingdom | Series A, Series B, Seed | Software, Cyber Security, Enterprise Software | $1.5M–$33M |
|
Cancer Focus Fund
VC Fund
|
2 | Israel, United States, Germany | Venture - Series Unknown, Series A, Seed | Biotechnology, Medical, Health Care | $4.5M–$47M |
|
Johnson & Johnson Robotics and Digital Solutions
VC Fund
|
2 | United States, Israel, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $300k–$100M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
SICAR
VC Fund
|
2 | Israel, Germany | Series C, Venture - Series Unknown | Medical, Health Care, Life Science | $6M–$6M |
|
Genesis Park
VC Fund
|
2 | United States, Israel | Private Equity, Debt Financing | Health Care, Construction, Manufacturing | $2.5M–$200M |
|
Takeda Ventures
VC Fund
|
2 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $12M–$130M |
|
Bio Capital Impact Fund
VC Fund
|
2 | Israel | Venture - Series Unknown | Medical, Health Care, Life Science | $6M–$6M |
|
Pfizer
VC Fund
|
2 | United States, Israel, France | Series A, Post-IPO Equity, Seed | Biotechnology, Health Care, Pharmaceutical | $800k–$320M |
|
Minrav
VC Fund
|
2 | Israel, Malaysia | Series A | Health Care, Hospital, Wellness | $10M–$10M |
|
PeakBridge
VC Fund
|
2 | Israel, United States, United Kingdom | Series A, Seed, Series B | Food and Beverage, Health Care, Food Processing | $501k–$50M |
|
Pontifax
VC Fund
|
2 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.3M–$130M |
|
Grok Ventures
VC Fund
|
2 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Energy, Software | $941k–$151M |
|
Arancia International
VC Fund
|
2 | Israel, United States, Malaysia | Series A, Series B | Health Care, Biotechnology, Life Science | $7.5M–$17M |
|
Office of the Chief Scientist
VC Fund
|
1 | Israel | Seed, Grant, Non-Equity Assistance | Health Care, Biotechnology, Medical Device | $27k–$1.3M |
|
Talisman Capital Partners
VC Fund
|
1 | United States, Israel, Hong Kong | Series A, Seed, Series B | Health Care, Information Services, Pet | $15M–$63M |
|
TPY Capital
VC Fund
|
1 | Israel, United States, France | Seed, Series A, Series B | Software, Artificial Intelligence, Analytics | $3.5M–$64M |
|
GoodPaper Ventures
VC Fund
|
1 | Series A | Legal, Legal Tech, E-Signature | ||
|
Khosla Ventures
VC Fund
|
1 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | |
|
ReGen Ventures
VC Fund
|
1 | United States, Austria, United Kingdom | Seed, Series A, Series B | Agriculture, Biotechnology, Farming | |
|
Terra Venture Partners
VC Fund
|
1 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Machine Learning, Software | |
|
Arkin Holdings
VC Fund
|
1 | Israel, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$95M |
|
Clal Biotechnology Industries
VC Fund
|
1 | Israel, United States | Series A, Series B | Health Care, Biotechnology, Medical Device | $4M–$55M |
|
Remiges Ventures
VC Fund
|
1 | United States, Japan, Canada | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $2.6M–$41M |
|
Arix Bioscience
VC Fund
|
1 | United States, United Kingdom, France | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $20M–$153M |
|
M Ventures
VC Fund
|
1 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
RM Global Partners
VC Fund
|
1 | Israel, United States | Series A, Series B | Biotechnology, Health Care, Life Science | $18M–$140M |
|
Trust Ventures
VC Fund
|
1 | United States, Brazil, Israel | Seed, Series A, Series B | Health Care, Software, Information Technology | $3.2M–$200M |
|
3B Future Health Fund
VC Fund
|
1 | United States, Italy, United Kingdom | Series B, Series A, Seed | Biotechnology, Therapeutics, Medical | $2.8M–$75M |
|
Windham Venture Partners
VC Fund
|
1 | United States, Israel | Series B, Series C, Series A | Health Care, Medical, Medical Device | $4.3M–$101M |
|
Rationalwave Capital Partners
VC Fund
|
1 | United States, Israel, Trinidad and Tobago | Seed, Pre-Seed | Software, Analytics, Machine Learning | $1.3M–$8.8M |
|
Morningside
VC Fund
|
1 | United States, United Kingdom, China | Series A, Series B, Venture - Series Unknown | Health Care, Biotechnology, Medical | $3M–$80M |
|
Trendlines Group
VC Fund
|
1 | Israel, Singapore, United Kingdom | Seed, Venture - Series Unknown | Health Care, Biotechnology, Medical Device | $650k–$62M |
|
Aries Holding BV
VC Fund
|
1 | The Netherlands, Canada, Israel | Seed, Pre-Seed | E-Commerce, SaaS, Fashion | $541k–$3M |
|
NextLeap Ventures
VC Fund
|
1 | Israel, United States | Seed, Series A, Venture - Series Unknown | Software, Health Care, Big Data | $450k–$26M |
|
Forbion Capital Partners
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
HBL Hadasit Bio Holdings
VC Fund
|
1 | Israel | Venture - Series Unknown, Seed, Series A | Biotechnology, Medical, Health Care | $10M–$47M |
| Access all 138 investors in Israel Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Grant, Seed, Pre-Seed
- Geography: Israel, United States, Mali
Investor stats
- Total investments: 217
- Round size: Seed $400k–$6M; Grant $130k–$3.5M; Pre-Seed $100k–$2.1M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $10M in 2023
Portfolio highlights
- Brevel — Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed.
- PulseNmore — Pulsenmore (TASE:PULS) is a world leader in self-scan ultrasound devices for remote clinical diagnosis and screening.
- GeoRank Studio — Get your business ranked on Google, cited by ChatGPT & Perplexity, and protected from reputation damage. Specialist SEO and GEO agency. Free consultation.
Early Stage VC
Show more...Investment focus
- Industry: Software, Biotechnology, Analytics
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 22
- Round size: Seed $1.3M–$10M; Pre-Seed $305k–$800k; Series A $10M–$40M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
- Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
- DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 80
- Round size: Series A $5.7M–$82M; Series B $22M–$93M; Series C $30M–$82M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — raised $340M in 2022
Portfolio highlights
- Lin Health — Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction results.
- Connie Health — At Connie Health, our Medicare advisors help older Americans find the right Medicare plan - all at no cost to you.
- Hopscotch Primary Care — We provide primary care services to seniors on Medicare, offering more time with your doctor, and a full care team to support all of your healthcare needs.
Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Life Science
- Stage:Seed, Series B, Series F
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
- Splisense — Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs), restore and modify protein functionality, addressing untreatable pulmonary diseases.
- Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 727
- Round size: Series A $9.8M–$140M; Series B $24M–$148M; Series C $19M–$160M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Acceleron Pharma — At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
- Insilico Medicine — Artificial Intelligence for Drug Discovery and Aging Research
FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Therapeutics
- Stage:Seed, Venture - Series Unknown
- Geography: Israel
Investor stats
- Total investments: 10
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- A2i Therapeutics — A2i Therapeutics develops novel therapeutic modulators of the protein that helps to control the immune response and neurological disorders.
- Skip Therapeutics — Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations.
- Selene Therapeutics — Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by the regulation of the neuronal activity set point by a reduction of the neuronal mean firing rate (MFR).Selene aims to develop small molecule inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrialmembrane and participating in several key cellular homeostatic processes.
Neo Ventures is a venture capital investment platform focused on deep tech, funds and high-growth startup portfolio.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 20
- Round size: Seed $500k–$2.9M; Series A $2.3M–$24M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Bulbi — Bulbi is a child development platform designed to help parents discover online and face-to-face educational activities for their children.
- Convex — All gas, no breakages. Convex is the reactive backend platform that keeps up with you and your agents.
- Extend Robotics — Extend Human Capabilities Beyond Physical Presence
RMGP Biopharma Investment Fund is an investment Fund
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Therapeutics
- Stage:Seed, Series B, Venture - Series Unknown
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Circuit-Bio — Circuit-Bio is a synthetic biology company developing a unique platform of logical gene circuits for cancer immunotherapy. The platform used by the company focuses on creating gene circuits that can precisely and locally manufacture a combination of several immune-stimulating proteins (immunomodulators) that are only expressed in specific tumorcells. The circuit turns cancer cells into "Trojan horses" that are used as anti-tumor resources and incite a potent, long-lasting immune response.
- Skip Therapeutics — Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations.
- Selene Therapeutics — Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by the regulation of the neuronal activity set point by a reduction of the neuronal mean firing rate (MFR).Selene aims to develop small molecule inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrialmembrane and participating in several key cellular homeostatic processes.
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series B, Series A, Series C
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 321
- Round size: Series A $4M–$47M; Series B $8.1M–$55M; Series C $8.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Convizit — Convizit's AI automatically captures user actions, adds properties, and delivers this behavioral data directly into your analytics and marketing platforms.
- Connie Health — At Connie Health, our Medicare advisors help older Americans find the right Medicare plan - all at no cost to you.
- QuantHealth — Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services.
Grove Ventures is a leading early-stage venture capital fund in Israel. It partners with seed and early-stage founders
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 75
- Round size: Seed $3.5M–$20M; Series A $8M–$50M; Series B $22M–$74M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $1.5M in 2024
Portfolio highlights
- LimitlessCNC — Limitless CNC is an AI-powered technology intended to improve CNC machining operations. It offers an AI CAM agent that works with NX-CAM to give industry-specific strategies and operations.
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
- FormX — California's trusted sustainable builders. FormX delivers fully customized single-family homes, ADUs, and backyard offices built faster with component-based modular construction.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, Norway
Investor stats
- Total investments: 44
- Round size: Seed $1.6M–$10M; Pre-Seed $300k–$6M; Series A $11M–$21M
- Lead/follow: 11% lead, 89% follow
- Last fund: Likely actively investing — fresh fund, raised $7.9M in 2025
Portfolio highlights
- Kimba — Kimba is an adaptive scent sleep system that uses sleep and biometric data to deliver personalized, natural-origin scents at specific moments throughout the night, designed to actively improve sleep rather than simply track it.
- CopilotKit — The Enterprise-Ready Frontend Stack for Agents. CopilotKit lets you integrate LLMs or agents with real-time context, UI control, and full flexibility.
- Shifters AI — Shifters builds autonomous robotic teams for dangerous ground missions.
Investing with conviction in visionary, technical founders inventing the future.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 68
- Round size: Seed $895k–$7M; Pre-Seed $575k–$2.8M; Series A $4.2M–$15M
- Lead/follow: 15% lead, 85% follow
- Last fund: Likely still investing — raised $40M in 2022
Portfolio highlights
- iOrganBio — The Right Cells. Consistently. At Scale.
- Extellis — Reliable Satellite Imagery at an Industrial Scale
- Bedrock Energy — Bedrock Energy is developing drilling technology and advanced subsurface simulation software to enable geothermal heating and cooling. The company develops autonomous drilling technology and advanced subsurface simulation software to make geothermal heating and cooling more widespread, affordable, and accessible.
An investment banking boutique, founded in 1978
Show more...Investment focus
- Industry: AgTech, Medical, Cannabis
- Stage:Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- GemmaCert — GemmaCert is a smart solution for testing cannabis potency, which unlike other solutions, is simple and sleek, for everyday use, requiring no specific skill-set for operation, and whose form gives little indication to the sophistication of the technology working underneath. GemmaCert is a bridge between technology and nature. This design createdthe desired attractive and useful man-machine interface for the best possible user experience along with a well-defined product with aesthetic presence without sacrificing on performance. GemmaCert is making a name for high performance, robustness, ease-of-use and reliability.No cannabis flower is the same, so before anyone consumes cannabis, they should have an understanding exactly what is in it and how it may affect them. From pharmacies in Germany, coffeeshops in Amsterdam, to supply chain stakeholders in North America, GemmaCert brings certainty and confidence to cannabis professionals, as well as consumers and patients worldwide.After over two years in research and development, GemmaCert started delivering first units to customers worldwide, primarily in North America and Europe. Revenues are generated from device sales and monthly subscription fees to our analytical service since GemmaCert units are operated and upgraded via secure cloud-based servers.
JVP is a top VC firm with $1.9B AUM and 165 companies built, leading in AI, Cyber Security, Fintech, Insurtech and Climatech.
Show more...Investment focus
- Industry: Software, Cyber Security, Enterprise Software
- Stage:Series A, Series B, Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 201
- Round size: Seed $1.5M–$8M; Series A $4.6M–$22M; Series B $10M–$33M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $15M in 2021
Portfolio highlights
- Reduxio — Overcome data gravity with ionir, a Kubernetes Data Services platform built for enterprises and optimized to run in Kubernetes.
- ThetaRay — ThetaRay's big data analytics solutions are based on AI & machine learning, empowering businesses to find opportunities and threats hidden in their big data
- Altair Semiconductor — Altair is a fabless semiconductor company based in Israel that is developing state of the art, ultra low power mobile WiMAX silicon solutions optimized for handsets and handheld devices.Altair was founded in May 2005 by former Texas Instruments executives with extensive broadband and wireless silicon experience. Their products are thesmallest, lowest power solutions in the industry, offering superb mobility performance and enabling the migration of WiMAX from a fixed wireless PC technology to a true next generation mobile technology.Altair's management and technology executives were among the founding team of Libit Signal Processing, a fabless chip company acquired by Texas Instruments in 1999 for $365 million. The company's world class scientists, algorithm, VLSI and software engineers have in the past, jointly developed over twenty complex mixed-signal silicon products, spanning six different broadband wired and wireless technologies.Altair is a principal member of the WiMAX Forum and a member of the IEEE802.16e.
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: Israel, United States, Germany
Investor stats
- Total investments: 10
- Round size: Series A $5.4M–$28M; Venture - Series Unknown $4.5M–$47M
- Lead/follow: 60% lead, 40% follow
- Last fund: Likely actively investing — fresh fund, raised $23M in 2025
Portfolio highlights
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.
Healthcare innovation wherever it originates.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 80
- Round size: Series A $5.9M–$63M; Series B $18M–$55M; Series C $300k–$100M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
- Manus Neurodynamica — Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.
- Glyphic Biotechnologies — We sequence proteins. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolution to enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of life itself.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
SICAR
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series C, Venture - Series Unknown
- Geography: Israel, Germany
Investor stats
- Total investments: 3
- Round size: Venture - Series Unknown $6M–$6M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Genesis Park is a Houston-based private equity firm focusing on buyouts, partnering strategies with public corporations, and growth financing. We bring capital, commercial execution capabilities and a depth of experience in mergers and acquisitions.We are opportunistic within market sectors where we have depth and exposure. Those sectors includetelecommunications, energy technology and media. Energy technology is a rapidly expanding category, and our Houston base allows us to marry traditional and alternative techniques in upstream and downstream environments. Founded in 2000, Genesis Park has used discipline and patience to build value for our investors, regardless of prevailing market conditions. We are consistently active in our portfolio companies, listening, learning and adding value by working alongside management. While our preference is to partner with an existing management team, we commonly source additional talent to optimize the existing opportunity.
Show more...Investment focus
- Industry: Health Care, Construction, Manufacturing
- Stage:Private Equity, Debt Financing
- Geography: United States, Israel
Investor stats
- Total investments: 24
- Round size: Debt Financing $5.5M–$65M; Private Equity $2.5M–$200M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely actively investing — fresh fund, raised $55M in 2026
Portfolio highlights
- Procare Ambulance — Official Twitter account of Procare Ambulance of Maryland.
- T&R Recovery Group — Founded in 2022 by Thomas Isbell and Roy M. Serpa, T&R Recovery Group is committed to revolutionizing the landscape of trauma, addiction, and mental
- GLASS BOX TECHNOLOGY INC — Glass Box Technology Inc offers customizable network, storage, security, and server solutions designed to meet the needs of the industries.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $12M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Global impact fund focusing on biotech, medtech and agritech investments that make a difference
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Venture - Series Unknown
- Geography: Israel
Investor stats
- Total investments: 2
- Round size: Venture - Series Unknown $6M–$6M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Post-IPO Equity, Seed
- Geography: United States, Israel, France
Investor stats
- Total investments: 58
- Round size: Seed $800k–$11M; Series A $4M–$310M; Post-IPO Equity $25M–$320M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
- Promise Bio — Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases.
- RNT Health Insights — RNT Health Insights is developing an AI assisted detection tool, that aids endoscopists in the real-time detection of debilitating upper gastrointestinal lesions, including early gastric cancer and associated malignant lesions, having received the US FDA Breakthrough Device Designation for their product.
Minrav provides engineering and construction services.
Show more...Investment focus
- Industry: Health Care, Hospital, Wellness
- Stage:Series A
- Geography: Israel, Malaysia
Investor stats
- Total investments: 4
- Round size: Series A $10M–$10M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.
PeakBridge is a highly networked, global impact VC that funds and connects the people, technology and processes that will shape the future of food. We invest in visionary pioneers, from early stage to Series A-B, with scalable, protectable climate and health-focused technologies. At their core: a deep commitment to disrupting our food system whiledriving positive impact. Our team is spread across seven countries and includes pioneers of FoodTech investment and decades of deep Agri-Food operational and financial experience. Together, we create exceptional value for bold FoodTech entrepreneurs and investors. A member of the Edmond de Rothschild Private Equity partnership, PeakBridge is also the only venture capital firm that is an official partner of the world’s largest Agri-Food innovation initiative, EIT Food.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Series A, Seed, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $501k–$11M; Series A $4.5M–$17M; Series B $11M–$50M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely still investing — raised $187M in 2022
Portfolio highlights
- Myota — Myota is a science and tech-based platform that develops fiber-based microbiome interventions to treat and prevent chronic disease. Myota was founded in 2019 and was headquartered in London, England.
- Ilant Health — We offer a comprehensive solution that take the stress and stigma out of obesity treatment. We increase access, improve quality, and drive reduction in total cost of care.
- KÄÄPÄ Biotech — Medicinal mushrooms, biotechnology, mycology, forestry, agroforestry, and food production.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 122
- Round size: Series A $6.3M–$110M; Series B $20M–$130M; Series C $22M–$101M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
- Otic Pharma — Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing anasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Energy, Software
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 70
- Round size: Seed $941k–$10M; Series A $3.5M–$63M; Series B $26M–$151M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Endolith — Endolith is a biotech company transforming sustainable mining by leveraging microbes, synthetic biology, and cloud computing to extract more critical minerals like copper from low-grade ores. Working with the many of the leading mining companies, Endolith is advancing its innovative technology to commercial scale. Recognized as a finalist in theBHP Unearthed BioMetals cohort and a member of the Alaska Critical Minerals Collaborative, Endolith is driving the future of mining with sustainable, efficient, and responsible solutions for the clean energy transition.
- MAKO — Solving human problems with nature’s surfaces.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States, Malaysia
Investor stats
- Total investments: 9
- Round size: Series A $10M–$17M; Series B $7.5M–$11M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.
The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Grant, Non-Equity Assistance
- Geography: Israel
Investor stats
- Total investments: 14
- Round size: Seed $50k–$1M; Grant $27k–$1.3M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- GalaPro — App for accessibility and translation services for live shows and theater. Automated closed captions, audio description and translation every performance
- Hargol™ FoodTech — Hargol™ FoodTech is the world's first commercial grasshopper farm! Grasshoppers are nature's most efficient protein source.Hargol™ FoodTech revolutionize the protein ingredient industry by providing a healthier and more sustainable and affordable alternative, becoming the leading intensive rearing company of grasshoppers in the world.The company is at the forefront of high quality nutrients and healthy grasshoppers supply to markets around the world, improving current market wild-harvested supply by providing year-round availability, nutrients content & quality and costs reduction.For its first line of products, Hargol FoodTech relies on methods and technologies of intensive breeding and growing of three grasshopper species that are processed into protein powders. The company is offering grasshopper based protein ingredient in North America markets to food/ingredient manufacturers and whole grasshoppers.Hargol™ FoodTech have thus far been attracting the interest of food producers, distributors and retailers in the North America, Europe and other regions of the world with whole grasshoppers, grasshopper’s nutrient-rich powder and innovative food products.With the expected 70% rise in demand for animal source protein over the next decades and with existing animal source protein taking a big toll on the environment there is a need for an alternative – Both sustainable and affordable for populations around the globe.Enhanced by their vegetarian diet grasshoppers’ nutrient content is superior compare to other insects or animal source protein: Over 70% whole protein, Omega-3 & Omega-6, Zinc, Iron, & Folic acid. Grasshoppers are also the only Kosher and Halal insect in the world!
- Magentiq Eye Ltd — AI assisted colonoscopy by MAGENTIQ EYE set a new standard of , recognized by the gastroenterology community for its superior performance.
Talisman Capital Partners operates as a private investment company.
Show more...Investment focus
- Industry: Health Care, Information Services, Pet
- Stage:Series A, Seed, Series B
- Geography: United States, Israel, Hong Kong
Investor stats
- Total investments: 7
- Round size: Series A $15M–$63M
- Lead/follow: 57% lead, 43% follow
Portfolio highlights
- Bond Vet — We offer compassionate, thorough, & friendly pet care in a warm, comfortable environment. Walk in or book online.
- Prilenia — Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston.
- qServe Communications — Own qserve.com today. Secure checkout and guided transfer support. No hidden fees.
TPY Capital is a Tel Aviv based early state VC, investing in some of Israel’s most talented entrepreneurs. They are active investors who typically lead rounds in the areas we invest in, which include data and analytics, digitization and human augmentation, fintech, and frontier tech such as quantum computing.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Analytics
- Stage:Seed, Series A, Series B
- Geography: Israel, United States, France
Investor stats
- Total investments: 41
- Round size: Seed $3.5M–$18M; Series A $5M–$26M; Series B $9M–$64M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $100M in 2019
Portfolio highlights
- Regatta — AI winners won't be decided by models; They'll be decided by data.
- Q-Factor — Q-Factor is building the world's first million-qubit quantum computer using neutral atom technology. Racing to unlock the full potential of quantum computing.
- Signals Analytics — Skai Ad Experiments
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!GoodPaper Ventures is a venture capital company that offers private equity and investment management services.
Show more...Investment focus
- Industry: Legal, Legal Tech, E-Signature
- Stage:Series A
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- OneNotary — Looking for a reliable and convenient on-demand online notary service? OneNotary platform offers fully legal and secure notarization services in all 50 states.
- Foresee Genomics — Foresee Genomics brings high-precision NGS to every lab with fast, affordable diagnostics that advance personalized care and unlock growth.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 981
- Lead/follow: no public data
Portfolio highlights
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
- Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.
- Point One Navigation — Precise Positioning for the next generation of transportation. 10cm accuracy everywhere.
Investing in the ReGeneration
Show more...Investment focus
- Industry: Agriculture, Biotechnology, Farming
- Stage:Seed, Series A, Series B
- Geography: United States, Austria, United Kingdom
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- Anthrogen — Anthrogen is a Biotechnology Research firm using bacteria and enzymes for reducing carbon in the air by transforming it into chemicals.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
- Differential Bio — Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.
We are an early stage venture capital firm dedicated to partnering with inspiring entrepreneurs to build breakthrough companies
Show more...Investment focus
- Industry: Artificial Intelligence, Machine Learning, Software
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 41
- Lead/follow: no public data
Portfolio highlights
- ViewNetic — ViewNetic is an AgTech startup developing unique imaging and machine learning technologies for early, pre-propagation detection of pests and diseases in high-value crops.
- Infiniplex — Infiniplex is an Israel-based startup whose mission is to utilize routine blood testing to screen for genetic tumor biomarkers and to offer preemptive, preventive, and follow-up cancer screenings at a more accessible and affordable cost. Our goal is to identify common and rare cancer types through a standard, inexpensive blood test that could becarried out as part of routine checkups, leveraging existing laboratory equipment and know-how. We aim to include tumor genomic testing as part of people's standard blood test checkups. The company was founded in 2021 and is based in Yokne'am Illit, Israel.
- Intuition Robotics — The AI care companion robot for older adults
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Israel, United States, Switzerland
Investor stats
- Total investments: 32
- Round size: Seed $2M–$6M; Series A $15M–$29M; Series B $23M–$95M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely actively investing — fresh fund, raised $100M in 2026
Portfolio highlights
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.
- Werewolf Therapeutics — Developing transformative conditionally activated proinflammatory immune modulating medicines to unleash a powerful attack on cancer.
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 18
- Round size: Series A $4M–$55M; Series B $15M–$40M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- TytoCare — TytoCare offers the Home Smart Clinic - for accessible, high-quality primary care from home, with no compromises.
- Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
- Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, Japan, Canada
Investor stats
- Total investments: 25
- Round size: Seed $2.6M–$10M; Series A $6.8M–$25M; Series B $8.2M–$41M
- Lead/follow: 64% lead, 36% follow
- Last fund: May invest from a new fund soon — raised $95M in 2019
Portfolio highlights
- Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
- Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
- Restore Vision — Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.
Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 38
- Round size: Series A $20M–$58M; Series B $45M–$137M; Series C $30M–$153M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Harpoon Therapeutics — At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 186
- Round size: Seed $2.4M–$24M; Series A $5.8M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Quintessent — Quintessent is developing optical connectivity solutions to scale computing and Artificial Intelligence (A.I.).
- Remepy — Redefining combination therapy by fusing traditional pharmaceuticals with clinically validated app-delivered protocols in a single, regulated prescription.
RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 4
- Round size: Series A $18M–$20M; Series B $32M–$140M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $61M in 2021
Portfolio highlights
- BIOMx — BiomX has moved to Tessera, bringing AI-driven intelligence, sensing and response together in one physical security platform.
- Mitoconix Bio — Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
- ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Trust Ventures is a venture capital firm that focuses on startups and provides knowledge and expertise in incumbent-heavy industries. The firm was founded in 2018 and is based in Austin, Texas, United States.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Brazil, Israel
Investor stats
- Total investments: 67
- Round size: Seed $3.2M–$23M; Series A $10M–$68M; Series B $9M–$200M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $10M in 2023
Portfolio highlights
- Fluxco — Procurement, leasing, service, and warranty for transformers from 100+ vetted global suppliers.
- Base Power — Base provides a battery-powered home energy service so you can enjoy power without interruption and save money. Now available in select regions of Texas.
- Antora Energy — Antora converts low-cost, intermittent renewable electricity into a reliable, on-demand source of zero-emissions industrial heat and power.
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series B, Series A, Seed
- Geography: United States, Italy, United Kingdom
Investor stats
- Total investments: 38
- Round size: Series A $2.8M–$41M; Series B $7.4M–$75M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
We focus on advances in medical technology and digital health to change the face of healthcare.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series B, Series C, Series A
- Geography: United States, Israel
Investor stats
- Total investments: 66
- Round size: Series A $4.3M–$101M; Series B $7M–$75M; Series C $12M–$73M
- Lead/follow: 12% lead, 88% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2025
Portfolio highlights
- PainTEQ — Explore PainTEQ's innovative solution for SI joint pain. Learn about the LinQ minimally invasive SI joint stabilization procedure, patient success stories, and our commitment to improving quality of life.
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- TailorMed — Moving Mountains for Patients
Rationalwave Capital Partners is a venture capital firm investing in technology companies both public and private. The firm is located in New York and founded by Mark Rosenblatt in 2003.
Show more...Investment focus
- Industry: Software, Analytics, Machine Learning
- Stage:Seed, Pre-Seed
- Geography: United States, Israel, Trinidad and Tobago
Investor stats
- Total investments: 12
- Round size: Seed $1.3M–$8.8M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Aromyx — Aromyx pioneers the creation of tastes and smells using a quantitative measurement system developed with biotechnology, data science, and AI.
- Brij — With one-touch, BRIJ allows consumers to gain product info, care instructions and discounts while you gain a deeper understanding of your consumer. Apps, paper manuals and hassles not required.
- BactoByte LTD — BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capability to improve outcomes, reduce mis-diagnostics, and lower health care costs.Based on a proprietary novel basic method, BactoByte’s assay delivers precise and cost-effective identification and direct antibiotics susceptibility testing with80-90% improvement of standard turnaround time.Time reduction, sensitivity, and specificity results in decreased mortality rates, fewer hospital days, and avoidance of associated costs of $1K-50K per patient.BactoByte has technology validation and partnerships with leading medical centers.
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 143
- Round size: Series A $6M–$45M; Series B $14M–$80M; Venture - Series Unknown $3M–$75M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Xealth — Connect your digital health vendors so doctors can order, deliver and monitor care from a single digital health integration platform.
- AdvanCell — AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.
- SimpliFed — SimpliFed provides virtual breastfeeding and baby feeding support fully covered by your health plan from pregnancy to weaning.
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Venture - Series Unknown
- Geography: Israel, Singapore, United Kingdom
Investor stats
- Total investments: 70
- Round size: Seed $650k–$4.1M; Venture - Series Unknown $1M–$62M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- IBI-Ag — We develop a wide array of selective bio-insecticides to help farmers grow more at lower cost with no harm to farm workers, consumers and the environment.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
financial holding company / investments
Show more...Investment focus
- Industry: E-Commerce, SaaS, Fashion
- Stage:Seed, Pre-Seed
- Geography: The Netherlands, Canada, Israel
Investor stats
- Total investments: 6
- Round size: Seed $1.3M–$3M; Pre-Seed $541k–$872k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Diptera — Developing technology to fight mosquitoes with mosquitoes.
- Green Story — Instantly quantify your fashion brand's environmental footprint, ensure global compliance, and streamline supply chain management. Elevate sustainability, gain competitive edge, and build trust with accurate, accessible data. Lead the charge in eco-friendly fashion with our unparalleled insights.
- Productpine — Discover, experience, and buy emerging brands and products from all over the world, at Productpine. Shop online through a personalized journey and be inspired!
NextLeap Ventures offers investors the opportunity to invest in early stage, Israeli high-tech startups, selected through its unique, highly vetted process.
Show more...Investment focus
- Industry: Software, Health Care, Big Data
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Israel, United States
Investor stats
- Total investments: 19
- Round size: Seed $450k–$26M; Series A $5.3M–$21M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Carrar — A complete thermal management solution for electric vehicles dissipating heat faster and more efficiently than ever before. Thermal management for ev batteries.
- Cybord — Cybord develops technologies that stop counterfeit, defective and malicious electronic components from getting assembled into products during the manufacturing process. Cybord scans each component prior to placement by integrating with electronic product manufacturing equipment, and deep learning algorithms rate each component based on Cybord’sglobal component database. Between 5 to 10% of all electronic components are considered counterfeit, responsible for up to 35% of RMAs. With Cybord, OEMs, EMSs, and distributors ensure their products are of high quality and free of hardware-cyber threats
- CorrActions — CorrActions' driver analyser connects to any in-cabin motion sensor such as the steering wheel, a smart watch, a smart phone etc. The driver analyser asseses the drivers' cognitive state in real time.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 219
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$111M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fresh fund, raised $606M in 2026
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 11
- Round size: Venture - Series Unknown $10M–$47M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
Life Science Investor funding in Israel at a glance
Stats across 116 deals from 138 investors.
Access all 138 investors in Israel Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Israel investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 138 investors investing in Israel Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!